Phillip Frost, chairman and CEO of Opko Health, has filed 75 Form 4 transactions across five companies, with a clear and persistent buy bias. His open-market purchases total roughly $15 million, while his only sales amount to about $55,800, a negligible figure against the buying. The recent activity, 23 straight open-market purchases with zero sales, shows the direction has not changed.
The bulk of the buying has concentrated in two tickers: OPK and COCP. On November 20 and 21, 2025, Frost executed 15 separate open-market purchases of Opko Health stock, with individual transaction values ranging from $2,363 to $281,890. Combined, those two days of OPK buying exceeded $1.5 million. The COCP purchases, for Cocrystal Pharma, have been smaller but more frequent. Frost bought COCP shares on at least nine separate dates between November 25, 2025 and August 5, 2026, with individual values from $1,500 to $70,590. The most recent COCP purchase came on August 5, 2026 at $9,816.
The remaining transactions are compensation-related. Frost received grants with a zero dollar value in NNUP on September 11, 2026 and in COCP on January 9, 2026, coded as "A" for awards. Those are not purchases. The total acquired value of $559,128 includes option exercises and conversions, which are mechanical events rather than conviction buys. The pattern across the filings is consistent: Frost has put new cash into OPK and COCP repeatedly over the past year, and he has not sold any shares in the recent window.
AI-assisted summary